secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0000012208-23-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q4 revenue flat YoY; non-GAAP EPS $3.31, guides FY2023 ~6-7% growth
---------------------------------------------------------------------------

- Q4 net sales $730.3M, -0.3% reported; currency-neutral +5.8% (+10.6% ex-COVID).
- Life Science segment $359.7M (+10.1%); Clinical Diagnostics $369.6M (-8.7%).
- GAAP net income $827.7M ($27.78 diluted) from Sartorius fair value; non-GAAP net income $98.5M ($3.31).
- Full-year 2022 net sales $2,802.2M (-4.1%); non-GAAP EPS $14.42 vs $15.94 prior year.
- FY2023 outlook: non-GAAP currency-neutral revenue growth ~6-7%, non-GAAP operating margin ~19.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/0000012208-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220823000025/bio-20230216.htm
  HTML page:      https://secwatch.observer/filing/0000012208-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer